Research programme: developmental pathway inhibitors - ChemRar Pharma
Latest Information Update: 16 Jul 2016
At a glance
- Originator ChemDiv
- Developer Chemical Diversity Research Institute; ChemRar Pharma; Neuronascent
- Mechanism of Action Neurotransmitter modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in Russia
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Russia
- 06 Nov 2009 Early research in Neurodegenerative disorders in Russia (unspecified route)